Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease

SIMPLE SUMMARY: In patients with inflammatory bowel disease, chronic inflammation is a risk factor for the development of digestive and nondigestive cancers. The treatment, as in patients without inflammatory bowel disease, is a combination of chemotherapy and targeted treatments, such as bevacizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrera-Gómez, Ruth Gabriela, Grecea, Miruna, Gallois, Claire, Boige, Valérie, Pautier, Patricia, Pistilli, Barbara, Planchard, David, Malka, David, Ducreux, Michel, Mir, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220809/
https://www.ncbi.nlm.nih.gov/pubmed/35740579
http://dx.doi.org/10.3390/cancers14122914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220809/
https://www.ncbi.nlm.nih.gov/pubmed/35740579
http://dx.doi.org/10.3390/cancers14122914

Ejemplares similares